+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Armagen - logo

ArmaGen is a privately held, clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Currently, ArmaGen has eight compounds in development. The company’s lead product candidates are AGT-182 for Hunter syndrome, which is in Phase 1 clinical trials, and AGT-181 for Hurler syndrome, which is in Phase 2 trials. ArmaGen’s headquarters and research operations are located in Calabasas, CA.

Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights - Product Thumbnail Image

Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights

  • Report
  • March 2019
  • 220 Pages
  • Global
From
Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights - Product Thumbnail Image

Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

  • Report
  • May 2018
  • 204 Pages
  • Global
From
Wearable Injectors Market (7th Edition): Distribution by Type of Device (Patch Pump / On Body Injector and Wearable Infusion Pump), Usability, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035 - Product Thumbnail Image

Wearable Injectors Market (7th Edition): Distribution by Type of Device (Patch Pump / On Body Injector and Wearable Infusion Pump), Usability, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Report
  • August 2023
  • 664 Pages
  • Global
From
Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Stroke Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 580 Pages
  • Global
From
Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 49 Pages
  • Global
From
Stroke - Pipeline Review, H2 2020 - Product Thumbnail Image

Stroke - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 773 Pages
  • Global
From
Loading Indicator